<DOC>
	<DOC>NCT02170337</DOC>
	<brief_summary>A randomized, double-blind, ascending multiple dose study in healthy volunteers and subjects with chronic rhinosinusitis with nasal polyps</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps</brief_title>
	<detailed_description />
	<mesh_term>Polyps</mesh_term>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Nasal Polyps</mesh_term>
	<criteria>Healthy Volunteers: Healthy males and females witha BMI between 18.0 and 32.0 kg/m2, inclusive subject with evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with study evaluation, procedures, or completion. Subjects with chronic rhinosinusitis with nasal polyps (CRSwNP): diagnosis of CRSwNP (inflammation of the nose and paranasal sinuses characterized in adults by 2 or more symptoms, 1 of which should be either nasal blockage or nasal discharge and/or facial pain and/or reduced smell for greater than 12 weeks) bilateral nasal polyps of grade 3 or 4 Forced Expiratory Volume (FEV1) &lt;/= 70% Asthma exacerbation requiring systemic corticosteroid treatment or hospitalization for &gt; 24h for treatment of asthma, within 3 months prior to screening or are on a dose of greater than 1000 Î¼g fluticasone.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>